Teva Pharmaceutical no stranger to the courts, is on a bit of a losing streak trying to protect its lead multiple sclerosis drug, Copaxone. Because the company focuses on low margin generic drugs, its branded MS drug brings in a roughly fifth of Teva's revenue, but alarmingly nearly half of its profit.
Teva is doing its best to delay generic competition while racing to convert existing Copaxone users to its new 3 times weekly formulation versus the current once a day variant. However, it may be running tight on time as this latest court decision to not impose clinical testing on copycat drugs, went against Teva. Generics could be on the way soon from Momenta (Nasdaq: MNTA), Mylan (Nasdaq: MYL) , and Novartis, but an "at-risk" launch could cost them depending future court decisions.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass discuss the results of this court fight, what it means for investors in both stocks, and why Teva is taking it all the way to the Supreme Court.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
The article Supreme Court + Risky Drug Launch = Billions at Stake originally appeared on Fool.com.David Williamson owns shares of Novartis. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.